SDC2 and TFPI2 Gene Methylation Joint Detection Kit ( Fluorescent PCR Method )
DNA methylation is a kind of epigenetic modification, and specific methylation changes occur in the genome of tumor cells. When colorectal cancer occurs, the methylation level of some genes (such as SDC2) will increase or decrease. By detecting the methylation status of these genes, the risk of colorectal cancer can be determined.
Every day, more than 108 intestinal epithelial cells are shed from the intestinal wall and excreted with feces through large bowel peristalsis in adults. The feces of patients with intestinal tumors contain a large number of diseased cells and abnormal cell components. Studies have found that methylation modification of gene promoters is an early event in tumorigenesis, and genetic material obtained from fecal samples of colorectal cancer patients can reflect the presence of intestinal cancer at an earlier stage.
Geneture methlyation detection kit uses methylation-specific multiplex PCR-fluorescent probe method to qualitatively detect the methylation of SDC2 and TFPI2 genes in intestinal exfoliated cells in human fecal samples. The test results are for clinical reference only.
Model：24T/48T/96T
- SKU: 0201612
- Category: Nucleic Acid Detection Kit
Colorectal Cancer Screening:
Expert consensus:
《Chinese Expert Consensus on Early Colorectal Cancer Screening Process (2019)》: Lists "stool DNA methylation testing" as an optional modality (evidence level II, recommendation grade B).
《2024 Chinese Community-Based Screening Consensus》: Recommends the combined fecal immunochemical test-DNA (FIT-DNA) assay as the primary community screening tool, with SDC2/TFPI2 methylation as its core methylation markers.
Target population:
1. Individuals aged 40 years and above
2. First-degree relatives with a history of colorectal cancer
3. Persons presenting relevant symptoms (e.g. rectal bleeding, mucous stools, constipation, diarrhea, narrowed stools, abdominal pain, etc.)
4. Individuals with a personal history of colorectal cancer or any malignant tumor
5. Those with a history of precancerous diseases of colorectal cancer (colorectal adenoma, inflammatory bowel disease, colorectal polyps, etc.)
6. Family history of hereditary colorectal polyposis syndromes
7. Unexplained anemia or weight loss
8. History of chronic appendicitis or appendectomy, chronic biliary disease, or cholecystectomy
Additional Information
Product Features:
1. Early diagnosis: early detection of colorectal cancer and even precancerous lesions can be achieved before patients have obvious discomfort symptoms, and ultra-early intervention can be achieved.
2. Convenient operation: using fluorescence quantitative PCR technology, the detection process is standardized, the laboratory operation is relatively simple, the result interpretation is intuitive, suitable for large-scale screening application.
3. Non-invasive: only need one tube of stool can be used for detection, which avoids the introduction and complicated process of traditional colonoscopy, improves the acceptance and compliance of patients, and is especially suitable for people who have concerns about colonoscopy.
4. Precision: double gene targets, adding human internal standard for whole process monitoring to improve the accuracy of test results.
5. High sensitivity and good specificity: the kit uses real-time fluorescence PCR technology, the detection sensitivity of colorectal cancer is 95.5%, the specificity is 90.3%, which is significantly higher than the traditional detection method, and can effectively reduce missed diagnosis and misdiagnosis.
6. Strong anti-interference: high repeatability and accuracy are still maintained under sample quality fluctuations.
Storage Condition:
The temperature during transportation should not be higher than -15~-20 °C. The kit should be placed at -20 °C ±5 °C, protected from light, and valid for 12 months.
Send an Inquiry
Your email address will not published. Required fieled are marked.
Related Products
Check out other related DNA/RNA Extraction Products
